571 related articles for article (PubMed ID: 10943516)
1. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
2. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
Groll AH; Müller FM; Piscitelli SC; Walsh TJ
Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
[TBL] [Abstract][Full Text] [Related]
3. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
4. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
5. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
7. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B lipid preparations: what are the differences?
Adler-Moore JP; Proffitt RT
Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
[TBL] [Abstract][Full Text] [Related]
9. Use of liposomal amphotericin B in bone marrow transplant.
Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
[TBL] [Abstract][Full Text] [Related]
10. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
11. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment.
Falci DR; dos Santos RP; Wirth F; Goldani LZ
Mycoses; 2011 Mar; 54(2):91-8. PubMed ID: 19878457
[TBL] [Abstract][Full Text] [Related]
13. [New aspects in treatment of systemic mycoses].
Presterl E; Graninger W
Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
[TBL] [Abstract][Full Text] [Related]
14. Lipid formulations of amphotericin B.
Jones E; Goldman M
Cleve Clin J Med; 1998 Sep; 65(8):423-7. PubMed ID: 9769563
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B for fever and neutropenia.
Winston DJ; Schiller GJ; Territo MC
N Engl J Med; 1999 Oct; 341(15):1154-5. PubMed ID: 10515755
[No Abstract] [Full Text] [Related]
16. Liposomal amphotericin B for fever and neutropenia.
Rakita R
N Engl J Med; 1999 Oct; 341(15):1153-4; author reply 1154-5. PubMed ID: 10515754
[No Abstract] [Full Text] [Related]
17. The use of lipid formulations of amphotericin B for systemic fungal infections.
Leenders AC; de Marie S
Leukemia; 1996 Oct; 10(10):1570-5. PubMed ID: 8847891
[TBL] [Abstract][Full Text] [Related]
18. The lipid formulations of amphotericin B.
Herbrecht R; Natarajan-Amé S; Nivoix Y; Letscher-Bru V
Expert Opin Pharmacother; 2003 Aug; 4(8):1277-87. PubMed ID: 12877636
[TBL] [Abstract][Full Text] [Related]
19. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
20. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence.
Bellmann R; Egger P; Wiedermann CJ
Clin Infect Dis; 2003 Jun; 36(11):1500-1. PubMed ID: 12766850
[No Abstract] [Full Text] [Related]
[Next] [New Search]